PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
The Journal of Clinical Hypertension10.1111/jch.129762017196627-631End-stage renal disease and adherence to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among patients with diabetesMichal Shani, Shlomo Vinker, Leonid Feldmanhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fjch.12976, http://onlinelibrary.wiley.com/wol1/doi/10.1111/jch.12976/fullpdf
European Heart Journal - Cardiovascular Pharmacotherapy10.1093/ehjcvp/pvaa064202072148-157A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockersAbhinav Grover, Mansi Oberoihttp://academic.oup.com/ehjcvp/advance-article-pdf/doi/10.1093/ehjcvp/pvaa064/33390220/pvaa064.pdf, http://academic.oup.com/ehjcvp/article-pdf/7/2/148/36599515/pvaa064.pdf, http://academic.oup.com/ehjcvp/article-pdf/7/2/148/36599515/pvaa064.pdf
10.21203/rs.3.rs-51043/v22020Angiotensin-converting enzyme inhibitors (ACEI) or Angiotensin receptor blockers (ARBs) may be safe for COVID-19 patientsWenjun Wang, Xiaohui Zhao, Wei Wei, Weiwang Fan, Kai Gao, Shengxiu He, Xijing Zhuanghttps://www.researchsquare.com/article/rs-51043/v2, https://www.researchsquare.com/article/rs-51043/v2.html
10.21203/rs.3.rs-51043/v12020Angiotensin-Converting Enzyme Inhibitors (ACEI) or Angiotensin Receptor Blockers (ARBs) May Be Safe for COVID-19 PatientsWenjun Wang, Xiaohui Zhao, Wei Wei, Weiwang Fan, Kai Gao, Shengxiu He, Xijing Zhuanghttps://www.researchsquare.com/article/rs-51043/v1, https://www.researchsquare.com/article/rs-51043/v1.html
Therapeutics and Clinical Risk Management10.2147/tcrm.s51762009547A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockersSu Hlinehttps://www.dovepress.com/getfile.php?fileID=5053
The Journal of Clinical Hypertension10.1111/j.1524-6175.2004.03446.x200466310-314Angiotensinā€Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Africanā€American Patients With HypertensionVasilios Papademetriou, Puneet Narayan, Peter Kokkinoshttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1524-6175.2004.03446.x, https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1524-6175.2004.03446.x, https://onlinelibrary.wiley.com/doi/full-xml/10.1111/j.1524-6175.2004.03446.x, https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1524-6175.2004.03446.x
Clinical Science10.1042/cs20210182202113581009-1014Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat?Fedor Simko, Tomas Bakahttps://portlandpress.com/clinsci/article-pdf/135/8/1009/908570/cs-2021-0182c.pdf, https://portlandpress.com/clinsci/article-pdf/135/8/1009/908570/cs-2021-0182c.pdf
Diabetes & Metabolic Syndrome: Clinical Research & Reviews10.1016/j.dsx.2020.04.0192020144349-350Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemicErkan Cure, Medine Cumhur Curehttps://api.elsevier.com/content/article/PII:S1871402120300850?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1871402120300850?httpAccept=text/plain
Encyclopedia of Heart Diseases10.1016/b978-012406061-6/50012-6200661-67Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor BlockersM. GABRIEL KHANhttps://api.elsevier.com/content/article/PII:B9780124060616500126?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:B9780124060616500126?httpAccept=text/plain
Journal of Travel Medicine10.1093/jtm/taaa0412020273Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19James H Diazhttp://academic.oup.com/jtm/advance-article-pdf/doi/10.1093/jtm/taaa041/32961230/taaa041.pdf, http://academic.oup.com/jtm/article-pdf/27/3/taaa041/33226377/taaa041.pdf, http://academic.oup.com/jtm/article-pdf/27/3/taaa041/33226377/taaa041.pdf